Reported Earlier, Abbisko And AstraZeneca Jointly Advance Novel IO-TKI Combination Therapy Evaluating Lumipodlin Plus Osimertinib In EGFR-Mu

Reported Earlier, Abbisko And AstraZeneca Jointly Advance Novel IO-TKI Combination Therapy Evaluating Lumipodlin Plus Osimertinib In EGFR-Mutated PD-L1 Positive NSCLC Patients